1 Llovet JM, "mRECIST for HCC : performance and novel refinements" 72 : 288-306, 2020
2 Gordan JD, "Systemic therapy for advanced hepatocellular carcinoma : ASCO guideline" 38 : 4317-4345, 2020
3 Kudo M, "Objective response by mRECIST is an independent prognostic factor for overall survival in hepatocellular carcinoma treated with sorafenib in the SILIUS Trial" 8 : 505-519, 2019
4 Kudo M, "Management of hepatocellular carcinoma in Japan : JSH consensus statements and recommendations 2021 update" 10 : 181-223, 2021
5 Iwamoto H, "Initial experience of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in real-world clinical practice" 13 : 2786-, 2021
6 Finn RS, "IMbrave150 : a randomized phase III study of 1L atezolizumab plus bevacizumab vs sorafenib in locally advanced or metastatic hepatocellular carcinoma" 36 (36): 2018
7 Ando Y, "Early tumor response and safety of atezolizumab plus bevacizumab for patients with unresectable hepatocellular carcinoma in real-world practice" 13 : 3958-, 2021